Syngene has announced that a Chromascan automated non-radioactive TLC plate reader is being used in the main manufacturing facility of a pharmaceutical company to improve its drug test accuracy.
The manufacturing plant in the UK is responsible for the worldwide supply of a range of therapies and is using the Chromascan system to automatically image fluorescent and visible TLC plates to test samples for purity, stability and content uniformity.
The samples tested include treatments for hypertension, arthritis and epilepsy, as well as the raw materials used in the manufacture of these drugs.
Using an automated system is helping to ensure the results are both reproducible and more accurate, which will in turn assure the content of each batch of drugs is safer.
The Chromascan installed in this pharmaceutical company is designed to increase throughput.
For this, the system features full process automation with a computer-controlled darkroom and camera.
Since the Chromascan was purchased with detailed Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) procedures, it has allowed staff in the pharmaceutical company to rapidly install and validate the system's performance on site so Chromascan can now be confidently used in a Good Manufacturing Practice (GMP) environment.
